Link Search Menu Expand Document

“Cancer patient survival can be parametrized to improve trial precision and reveal time-dependent therapeutic effects” by Deborah Plana, Geoffrey Fell, Brian M. Alexander, Adam C. Palmer, Peter K. Sorger. Nat Commun 13, 873 (2022).

“Predictable clinical benefits without evidence of synergy in trials of combination therapies with immune-checkpoint inhibitors” by Adam C. Palmer, Benjamin Izar , Haeun Hwangbo and Peter K. Sorger. Clin Cancer Res (2022) 28 (2): 368–377.